News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

Al's Comment:

 This small  study had amazing results.  Compared to matched historical controls, median progression free survival was  25.3 months in the vaccine group vs.   8.0 months in the historical control group and  median overall survival was 41.1 vs. 19.2 months.  Only 1 patient had significant side effects, an allergic reaction to the immune stimulant they used - which was discontinued and she was able to continue on the vaccine.

Disclaimer: I (Al Musella, DPM) am on the patient advisory board at The Preston Robert Tisch Brain Tumor Center.


Posted on: 04/14/2017

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740